Dupixent Approved for Allergic Fungal Rhinosinusitis Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy REGN?
Source: Newsfilter
- FDA Approval for New Indication: Dupixent (dupilumab) has received FDA approval as the first treatment specifically for allergic fungal rhinosinusitis (AFRS) in patients aged 6 and older, marking a significant breakthrough in treatment options.
- Clinical Study Support: The LIBERTY-AFRS-AIMS phase 3 study demonstrated that Dupixent significantly improved sinus opacification scores by 50% at 52 weeks compared to 10% in the placebo group, highlighting its efficacy in alleviating AFRS symptoms.
- Reduced Surgical Need: Dupixent led to a 92% reduction in the need for systemic corticosteroids and surgery over 52 weeks, which not only alleviates the treatment burden for patients but may also redefine the standard of care for AFRS by minimizing recurrence risks.
- Broad Indication Expansion: Dupixent is now approved for nine diseases driven by type 2 inflammation, further solidifying its critical role in treating chronic inflammatory diseases and is expected to benefit over 1.4 million patients globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 766.660
Low
637.00
Averages
808.50
High
1057
Current: 766.660
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
REGENERON ANTICIPATES PRICING OBESITY DRUG COMPETITIVELY WITH NON-CHOLESTEROL-LOWERING THERAPIES - TD COWEN CONFERENCE
Regeneron Drug Expectations: Regeneron anticipates that its obesity drug will be priced competitively, aligning closely with existing therapies in the market.
Comparison with Other Therapies: The new drug is expected to offer similar benefits to current treatments that do not provide cholesterol-lowering effects.
See More
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
EMA Recommends Dupixent Approval for Children with Chronic Urticaria
- Pediatric Indication Expansion: The European Medicines Agency's Committee recommends approval of Sanofi and Regeneron's Dupixent (dupilumab) for treating chronic spontaneous urticaria in children aged 2 to 11, marking a significant expansion in the drug's pediatric indications, which is expected to substantially boost market demand and sales.
- Clinical Trial Support: This recommendation is supported by data from the phase 3 LIBERTY-CUPID program, demonstrating Dupixent's efficacy against chronic spontaneous urticaria, further solidifying its position in the treatment landscape and likely attracting more prescriptions from healthcare providers.
- Existing Approval Status: Dupixent is already approved for chronic spontaneous urticaria in individuals aged 12 and older, and the expansion into pediatric indications will enable it to capture a larger share of the competitive market, enhancing the companies' influence in the pediatric pharmaceutical sector.
- Optimistic Market Outlook: With the application of Dupixent in the pediatric population, it is anticipated to drive long-term growth for both Sanofi and Regeneron, especially against the backdrop of rising demand for allergy-related medications, thereby further enhancing their competitiveness in the pharmaceutical industry.
See More
Dupixent Recommended for EU Approval to Treat Chronic Urticaria in Children
- EU Approval Recommendation: The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended Dupixent for treating chronic spontaneous urticaria (CSU) in children aged 2 to 11, marking it as the first targeted therapy for this age group, which is expected to significantly enhance the quality of life for affected children.
- Clinical Study Support: This recommendation is backed by data from the LIBERTY-CUPID clinical study program, including two phase 3 studies involving children aged 6 to 11, demonstrating Dupixent's efficacy in treating CSU, potentially offering new treatment options for children inadequately controlled by standard antihistamine therapy.
- Significant Market Potential: With over 1.4 million patients treated globally, approval in the EU would further solidify Dupixent's leadership in the chronic skin disease market and generate substantial revenue growth for Sanofi and Regeneron.
- Future Outlook: A supplemental biologics license application for Dupixent in the US has been accepted, with a final FDA decision expected by April 2026, which, if successful, would provide broader treatment options for pediatric CSU patients and further drive market demand.
See More
CRISPR Therapeutics Shares Surge on Strong Earnings and Pipeline Growth
- Significant Revenue Growth: CRISPR Therapeutics' gene-editing therapy Casgevy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand for treatments of sickle cell disease and transfusion-dependent beta thalassemia.
- Surge in Patient Treatments: In Q4, 64 patients received Casgevy infusions, with 147 initiating treatment in the first quarter of 2025, nearly tripling 2024 levels, suggesting that successful patient recruitment will drive substantial revenue growth in the future.
- Analyst Optimism: William Blair analyst Sami Corwin noted that the increase in first cell collections strengthens confidence in significantly higher revenue expectations for 2026, reflecting market confidence in CRISPR's future performance.
- Positive Technical Analysis: CRISPR Therapeutics' stock is currently trading 14.4% above its 20-day SMA and 3.0% above its 100-day SMA, indicating a strong short-term upward trend, while the stock has risen 33.31% over the past 12 months, approaching its 52-week highs.
See More
Regeneron Extends Title Sponsorship of Science Talent Search for Another Decade
- Sponsorship Renewal: Regeneron has announced the extension of its title sponsorship of the Regeneron Science Talent Search (STS) for another decade, committing to a 50% increase in investment, pledging an additional $150 million to inspire young scientists.
- Scholarships and Prizes: Since 2017, Regeneron and the Society have engaged over 20,000 young scientists and recognized 3,000 as scholars, awarding more than $31 million in prizes, highlighting its profound impact on science education.
- International Science and Engineering Fair: Regeneron will continue its sponsorship of the International Science and Engineering Fair (ISEF), with total investments in STS and ISEF expected to exceed $300 million by 2036, further solidifying its leadership in STEM education.
- Expanded STEM Impact: Since Regeneron became the title sponsor, participation in STS has increased by 49%, demonstrating a significant enhancement in the program's reach and impact on young scientists nationwide, fostering future scientific innovation.
See More
REGENERON ANTICIPATES PRICING OBESITY DRUG COMPETITIVELY WITH NON-CHOLESTEROL-LOWERING THERAPIES - TD COWEN CONFERENCE
Regeneron Drug Expectations: Regeneron anticipates that its obesity drug will be priced competitively, aligning closely with existing therapies in the market.
Comparison with Other Therapies: The new drug is expected to offer similar benefits to current treatments that do not provide cholesterol-lowering effects.
See More
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
EMA Recommends Dupixent Approval for Children with Chronic Urticaria
- Pediatric Indication Expansion: The European Medicines Agency's Committee recommends approval of Sanofi and Regeneron's Dupixent (dupilumab) for treating chronic spontaneous urticaria in children aged 2 to 11, marking a significant expansion in the drug's pediatric indications, which is expected to substantially boost market demand and sales.
- Clinical Trial Support: This recommendation is supported by data from the phase 3 LIBERTY-CUPID program, demonstrating Dupixent's efficacy against chronic spontaneous urticaria, further solidifying its position in the treatment landscape and likely attracting more prescriptions from healthcare providers.
- Existing Approval Status: Dupixent is already approved for chronic spontaneous urticaria in individuals aged 12 and older, and the expansion into pediatric indications will enable it to capture a larger share of the competitive market, enhancing the companies' influence in the pediatric pharmaceutical sector.
- Optimistic Market Outlook: With the application of Dupixent in the pediatric population, it is anticipated to drive long-term growth for both Sanofi and Regeneron, especially against the backdrop of rising demand for allergy-related medications, thereby further enhancing their competitiveness in the pharmaceutical industry.
See More
Dupixent Recommended for EU Approval to Treat Chronic Urticaria in Children
- EU Approval Recommendation: The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended Dupixent for treating chronic spontaneous urticaria (CSU) in children aged 2 to 11, marking it as the first targeted therapy for this age group, which is expected to significantly enhance the quality of life for affected children.
- Clinical Study Support: This recommendation is backed by data from the LIBERTY-CUPID clinical study program, including two phase 3 studies involving children aged 6 to 11, demonstrating Dupixent's efficacy in treating CSU, potentially offering new treatment options for children inadequately controlled by standard antihistamine therapy.
- Significant Market Potential: With over 1.4 million patients treated globally, approval in the EU would further solidify Dupixent's leadership in the chronic skin disease market and generate substantial revenue growth for Sanofi and Regeneron.
- Future Outlook: A supplemental biologics license application for Dupixent in the US has been accepted, with a final FDA decision expected by April 2026, which, if successful, would provide broader treatment options for pediatric CSU patients and further drive market demand.
See More
CRISPR Therapeutics Shares Surge on Strong Earnings and Pipeline Growth
- Significant Revenue Growth: CRISPR Therapeutics' gene-editing therapy Casgevy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand for treatments of sickle cell disease and transfusion-dependent beta thalassemia.
- Surge in Patient Treatments: In Q4, 64 patients received Casgevy infusions, with 147 initiating treatment in the first quarter of 2025, nearly tripling 2024 levels, suggesting that successful patient recruitment will drive substantial revenue growth in the future.
- Analyst Optimism: William Blair analyst Sami Corwin noted that the increase in first cell collections strengthens confidence in significantly higher revenue expectations for 2026, reflecting market confidence in CRISPR's future performance.
- Positive Technical Analysis: CRISPR Therapeutics' stock is currently trading 14.4% above its 20-day SMA and 3.0% above its 100-day SMA, indicating a strong short-term upward trend, while the stock has risen 33.31% over the past 12 months, approaching its 52-week highs.
See More
Regeneron Extends Title Sponsorship of Science Talent Search for Another Decade
- Sponsorship Renewal: Regeneron has announced the extension of its title sponsorship of the Regeneron Science Talent Search (STS) for another decade, committing to a 50% increase in investment, pledging an additional $150 million to inspire young scientists.
- Scholarships and Prizes: Since 2017, Regeneron and the Society have engaged over 20,000 young scientists and recognized 3,000 as scholars, awarding more than $31 million in prizes, highlighting its profound impact on science education.
- International Science and Engineering Fair: Regeneron will continue its sponsorship of the International Science and Engineering Fair (ISEF), with total investments in STS and ISEF expected to exceed $300 million by 2036, further solidifying its leadership in STEM education.
- Expanded STEM Impact: Since Regeneron became the title sponsor, participation in STS has increased by 49%, demonstrating a significant enhancement in the program's reach and impact on young scientists nationwide, fostering future scientific innovation.
See More
